Von Hippel-Lindau disease

MONDO:0008667

An autosomal dominant disorder caused by pathogenic variants in the VHL gene, leading to an increased risk of various benign and malignant tumors, including hemangioblastomas, retinal hemangiomas, endolymphatic sac tumors, renal cell carcinoma, and pheochromocytomas.

Also known as: Lindau disease, VHL, VHL-related von Hippel-Lindau disease, Von Hippel-Lindau syndrome, Von Hippel-Lindau syndrome (VHL), cerebroretinal angiomatosis, familial cerebelloretinal angiomatosis, von Hippel-Lindau disease

24 clinical trials for this condition and its sub-types.

Follow this condition — get notified about new trials

Broader categories

Disease (618) Nervous system disorder (217) Hereditary disease (172) Human disease (14) Hereditary neurological disease (5) Disease of genetic or genomic mechanism (2) Neurocutaneous syndrome (2) Autosomal dominant disease (0) Autosomal genetic disease (0) Disease by body system or component (0)

Trials to join now! 12 Not yet recruiting 1 Not yet finished but already full! 7 Completed 3 Terminated 1

Experimental kidney cancer drug trial halted early

Disease control Terminated

This early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Jun 27, 2026 09:09 UTC

Von Hippel-Lindau disease

Broader categories

Experimental kidney cancer drug trial halted early